Acknowledgements
Anderson Cancer, RP1100584, Cancer
ROAR, CANCER
The ROAR study was designed and data were analyzed by the sponsor (Novartis) in collaboration with the trial steering committee. Study funding was provided by Novartis. Writing and editorial assistance was provided by T. Jandoo, Novartis Healthcare Pvt. Ltd., India. The authors thank G. Gao for supporting data analysis for the manuscript. V.S., an Andrew Sabin Family Foundation Fellow at The University of Texas MD Anderson Cancer Center, acknowledges support from the Jacquelyn A. Brady Fund and is supported by National Institutes of Health grants R01CA242845 and R01CA273168. The MD Anderson Cancer Center Department of Investigational Cancer Therapeutics is supported by the Cancer Prevention and Research Institute of Texas (RP1100584), the Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy (1U01 CA180964), National Center for Clinical and Translational Sciences grant UL1 TR000371 and the MD Anderson Cancer Center Support Grant (P30 CA016672). This trial was originally designed and sponsored by GlaxoSmithKline. Novartis Pharmaceuticals Corporation is the current sponsor of the trial.